Erythromycin coadministration increases plasma atorvastatin concentrations

Journal of Clinical Pharmacology

Volumn 39, Issue 5, 1999, Pages 501-504

  Siedlik, Paul H ^a   Olson, Stephen C ^a   Yang, Bing Bing ^a   Stern, Ralph H ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ERYTHROMYCIN; GLYCOPROTEIN P;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILE SECRETION; BLOOD SAMPLING; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTILIPEMIC AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HALF-LIFE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES;

EID: 0032806143     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988;318(1):47-48.
2. Ayanian JZ, Fuchs CS, Stone RM: Lovastatin and rhabdomyolysis (letter). Ann Int Med 1988;109:682-683.
3. Wallace CS, Mueller BA: Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother 1992;26:190-192.
4. England JDF, Viles A, Walsh JC, Steward PM: Muscle side effects associated with simvastatin therapy. Med J Aust 1990;153:562-563.
5. Pichard L, Fabre I, Fabre G, Domergue J, Aubert BS, Mourad G, Maurel P: Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition 1990;18(5):595-606.
6. Michniewicz BM, Black AE, Sinz MW, Woolf TF: In vitro and in vivo metabolism of atorvastatin (CI-981). Data presented at the Sixth North American International Society for the Study of Xenobiotics, October 1994, Raleigh, NC.
7. Watkins PB: Noninvasive tests of CYP3A4 enzymes. Pharmacogenetics 1994;4:171-184.
8. The Warner-Lambert Company, Parke-Davis Pharmaceutical Research Division: Lipitor® (Atorvastatin Calcium) Tablets package insert.
9. Le Couteur DG, Martin PT, Pond SM, Bracs P, Black A, Hayes R, Woolf TF, Stern R: Metabolism and excretion of 14C atorvastatin in patient with T-tube drainage. Proceedings of the Australian Society of Clinical and Experimental Pharmacologists and Toxicologists 1996;3:153.
10. Wrighton SA, Ring BJ: Inhibition of human CYP3A catalyzed l'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994;11(6): 921-924.
11. Danan G, Descatoire V, Pessayre D: Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 1981;218(2):509-514.
12. Watkins PB, Wrighton SA, Maurel P, et al: Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci 1985;82:6310-6314.
13. Leveque D, Jehl F: P-glycoprotein and pharmacokinetics. Anticancer Res 1995;15:331-336.
14. Hofsli E, Nissen-Meyer J: Reversal of drug resistance by erythromycin: erythromycin increase the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer 1989;44:149-154.